PHAR

Pharming Group N.V. PHAR

NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #1,642 of 2,925

Why it scores 50Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$376.13M

Quarter to Dec 31

Net income

$2.85M

Quarter to Dec 31

Free cash flow

$53.96M

Quarter to Dec 31

Operating margin

6.9%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$4.27M total
MAC Alpha Capital Management, LP
$2.95MNew
Silverberg Bernstein Capital Management LLC
$577.1K-7.2%
Crossmark Global Holdings, Inc.
$169.0KNew
CITADEL ADVISORS LLC
$162.3K+17.5%
MORGAN STANLEY
$159.7K+0.1%
SmartHarvest Portfolios, LLC
$144.7K-3.5%
Knoll Capital Management, LLC
$56.8K+0.8%
Silver Grove Financial Group, Inc.
$14.9KNew
Nalls Sherbakoff Group, LLC
$12.1K0.0%
Global Retirement Partners, LLC
$6.3K--
Integrated Wealth Concepts LLC
$5.3KNew
BNP PARIBAS FINANCIAL MARKETS
$4.2K-25.0%
Optiver Holding B.V.
$4.1KNew
NewEdge Advisors, LLC
$2.6KNew
UBS Group AG
$542New
OSAIC HOLDINGS, INC.
$222-87.5%
Larson Financial Group LLC
$97-98.0%
Caitong International Asset Management Co., Ltd
$14New
See all 18 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

PHAR key financials by period

Reported revenue, net income and operating margin by fiscal year, from Pharming Group N.V.'s annual filings on SEC EDGAR.

Pharming Group N.V. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$376.1M$2.9M6.9%
FY 2024$297.2M$-11.8M-2.9%
FY 2023$245.3M$-10.5M-2.2%
FY 2022$205.6M$13.7M8.9%
FY 2021$198.9M$16.0M6.8%
FY 2020$212.2M$37.7M35.9%
Source: PHAR filings on SEC EDGAR →

Companies similar to PHAR

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

About Pharming Group N.V. (PHAR): stock profile, AI score and financials

Pharming Group N.V. (PHAR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PHAR at 49.9/100 on a composite quality score built from its SEC filings, placing it at rank #1,642 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Pharming Group N.V. reports quarterly revenue of $376.1M, net income of $2.9M, an operating margin of 6.9%. Top institutional holders of PHAR by reported 13-F value include MAC Alpha Capital Management, Silverberg Bernstein Capital Management, Crossmark Global, based on the most recent SEC filings. PHAR trades on the Nasdaq exchange and files with the SEC under CIK 1828316. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHAR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pharming Group N.V. directly from SEC EDGAR.

SEC EDGAR: CIK 1828316 →